Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Possibly this being a clinical trial drug they were warned in writing not to print or report any account so not to interfere.
That Ivermectin story is rehashed old news which started Oct8. Since then on October 14th the Drocks attorney said this- But, Huxtable said, another medication that hasn’t gotten FDA approval is being used to treat COVID-19 patients. Drock signed a special release so his wife could receive the drug Brilacidin, he told Nutt.
But, unlike Ivermectin, the FDA has allowed the drug to be used in clinical trials with hospitalized COVID-19 patients.
So by this Oct 14th account she would have started Brilacidin.
https://www.palmbeachpost.com/story/news/coronavirus/2021/10/13/covid-patients-request-ivermectin-denied-hospital-lawyer-claims/8437265002/
Agree the anticipated mid to and late October timeline on record was given to Leo. We are still in mid-October range.
These are clearly all forward looking achievements i.e. Capital Appreciation. I'm thinking feedback from B has been good.
"contingent upon the achievement of certain market capitalization, licensing revenue and clinical trial performance goals, and (ii) cash awards with a maximum value of up to $14.0 million, contingent upon the achievement of certain market capitalization and licensing revenue goals".
Go B
Isn't that the truth. At this point and time Leo takes performance based incentives in the midst of trial data coming any day while simultaneously allowing B for compassionate care use. I like it.
They'll become unhinged as Leo capitalizes on those performance based incentives i.e. licensing revenue and clinical trial performance goals. Go Leo bring home those results.
Agree. Nice going btw.
Pocket money but go ahead.
Nice. Now we see performance based incentives.
It's a way but not likely right now at our low share price. This would be something for a high value company to attract small investors
A forward split in a stock would increase the outstanding share count. Something I wouldn't consider happening right now at our low share price though.
Yep looking forward to excellent news.
I look forward to see what Mr. Ehrlich and Ipix have for their planning.
That ship is taking on water. Go B make covid go away.
Leo would have performance shares award, including clinical trial results. Sounds bullish. Go B
For what I've seen current soc is not worth spit in hospitalized patients.
It may just be helping some very sick persons. If it helps it's for the good of mankind regardless of ones stance against the company.
Depends on your slant. The statement said other patients are being treated so they also asked to receive B. Ivermectin has been in the news for months so people know about it. Blacidin has yet to get any press hopefully that's about to change. Body shutting down means close to death hopefully with the Lords help things get turned around.
When results are published I hope Leo also makes it clear that B's anti-viral abilities doesn't stop at covid-19. "Brilacidin has shown potent and consistent inhibition in vitro against coronaviruses, alphaviruses, bunyaviruses and adenoviruses (with lab testing against other viruses also underway), supporting Brilacidin’s development as a broad-spectrum antiviral".
I see it as pure Merck spam.
Next week starts mid-October everyone.
NO Reverse Split as Leo promised. So much fear mongering we must be getting close to results time. No one but God knows the future. Go Leo
I hope your your wrong too. B has a lot of promising research going for it. Hopefully all of us will be rewarded.
Just saw this Oct5 regarding Brilacidin https://www.precisionvaccinations.com/vaccines/brilacidin-covid-19-therapeutic
Personal is right the same mako vitriol on a daily basis.
Hmm your the same one that said in vitro failed. Now we Look forward to clinical data.
It's a anything but Brilacidin mentality.
One thing we can surely speculate is their current standard of care sucks. We all parties should allow for full assessment of B arm to even set a price.
Russia hits record number of deaths.
https://www.msn.com/en-us/news/world/russia-hits-record-number-of-daily-covid-19-deaths/ar-AAP67br?ocid=winp1taskbar
Ok thanks for that. I didn't view the comments.
Those facebook posts are as clear as mud. It didn't actually say whether the one patient actually received B. The other was reported as actually receiving B and some days later being virus free but with no other change in status. Virus free was good but nothing to hang your hat on without knowing more. Trial news is where the rubber meets the road on this.
Virus surge hits New England despite high vaccination rates
https://www.yahoo.com/news/delta-tearing-states-despite-high-115328590.html
Agree. The emergency waiting rooms can turn into a petri dish when waiting to be seen in cold and flu season. I had to wait four hours a few years ago to get seen for heart flutter. Bad part about me going to the hospital was I came down with the flu less then 3 days later was a rough go for about three weeks.
That's right it failed to help hospitalized patients.
April 15 2021 Merck said Thursday that it has seen “encouraging” results in a clinical trial of an antiviral pill to treat Covid-19 early in the disease’s course, but the pill failed to help hospitalized patients and must be used very early in the disease.
B proves out in the hospital it's a win win.
Agree. We need to better treat mild cases before they become full blown. An inhaler makes sense because covid really manifests itself in the airways.
So Merk's pill helps just 50% of mild cases when treated very early and none of the moderate cases. Hopefully B success would be the game changer for those that end up hospitalized. Billions is right.
Thanks you too. Hopefully B is the answer in moderate to severe patients. We need a heavy lifter.
Funny seeing a dr regarding Brilacidin a very promising drug to help hospitalized patients only in terms of valuation.
With today's less then stellar pill news I'm pretty stoked regarding our prospects. Go B